The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis

The purpose of this study is to evaluate the effectiveness and safety of liraglutide/liraglutide + metformin in overweight/obese women with polycystic ovary syndrome (PCOS). The related literatures published until April 2021 were searched in PubMed, Cochrane Library, MEDLINE and EmBase. Six randomized controlled trials of 127 related articles were obtained through searching. Three articles compared liraglutide with metformin, and four articles compared liraglutide combined with metformin with metformin. Our meta-analysis suggests that liraglutide was superior to metformin only in weight loss [MD = − 2.74, 95% CI (− 4.29, − 1.18), P = 0.0006]. Compared with metformin group, the combination group had significant advantages in weight loss [MD = − 3.81, 95% CI (− 5.16, − 2.46), P < 0.001], BMI [MD = − 2.59, 95% CI (− 3.12, − 2.07), P < 0.001], waist circumference [MD = − 6.26, 95% CI (− 7.79, − 4.72), P < 0.001], fasting blood glucose [MD = − 0.59, 95% CI (− 0.74, − 0.44), P < 0.001] and fasting insulin [MD = − 1.52, 95% CI (− 2.69, − 0.35), P = 0.01], while the incidence of adverse reactions was relatively high [RR = 2.91, 95% CI (1.55, 5.46), P = 0.00009]. The present results indicate that liraglutide and metformin have the similar effects in the treatment of overweight/obese PCOS patients. Liraglutide combined with metformin is more effective than metformin in improving PCOS, but it is necessary to master the correct medication method to reduce the occurrence of adverse reactions.